This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
by Zacks Equity Research
The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for the drug.
REGNNegative Net Change SNYNegative Net Change AZNNegative Net Change GSKPositive Net Change
pharmaceuticals
Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS' innovative pet care products, along with efforts to expand the business, are expected to fuel significant growth in the future.
ILMNNegative Net Change ZTSPositive Net Change KRYSNegative Net Change FULCNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
by Zacks Equity Research
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
NVSPositive Net Change PFENegative Net Change LLYNegative Net Change
medical pharmaceuticals
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
by Kinjel Shah
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
BIIBNegative Net Change NVONegative Net Change LLYNegative Net Change
pharmaceuticals
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
by Zacks Equity Research
ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.
BMRNNegative Net Change ILMNNegative Net Change ASNDNegative Net Change BVSNegative Net Change
biotechs medical pharmaceuticals
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
by Zacks Equity Research
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
NVSPositive Net Change PFENegative Net Change LLYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
by Zacks Equity Research
NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.
BMYPositive Net Change MRKNegative Net Change ILMNNegative Net Change NCNAPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
by Zacks Equity Research
ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
GSKPositive Net Change ILMNNegative Net Change FULCNegative Net Change ZNTLNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Lilly Gets FDA Approval for Eczema Drug Ebglyss
by Zacks Equity Research
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.
NVSPositive Net Change BIIBNegative Net Change PFENegative Net Change LLYNegative Net Change
pharmaceuticals
Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns
by Nalak Das
Three large-cap stocks ??? AES, PFE and UNM ??? currently offer attractive short-term returns along with a high dividend rate.
PFENegative Net Change UNMPositive Net Change AESPositive Net Change
insurance pharmaceuticals utilities
Incyte Announces Promising New Data on Oncology Candidate at ESMO
by Zacks Equity Research
INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.
INCYNegative Net Change SNDXNegative Net Change KRYSNegative Net Change FULCNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
by Zacks Equity Research
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
by Zacks Equity Research
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
MRKNegative Net Change SMMTNegative Net Change TILPositive Net Change BVSNegative Net Change
biotechs medical pharmaceuticals
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
by Zacks Equity Research
Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.
ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change IMRXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
by Zacks Equity Research
As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.
SNYNegative Net Change GSKPositive Net Change MRKNegative Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
by Kinjel Shah
Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.
SNYNegative Net Change JNJNegative Net Change TEVAPositive Net Change ABBVPositive Net Change
pharmaceuticals
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
by Zacks Equity Research
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
NVSPositive Net Change RHHBYPositive Net Change LLYNegative Net Change
biotechnology immuno-therapy medical pharmaceuticals
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
by Zacks Equity Research
GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.
GSKPositive Net Change GILDPositive Net Change KRYSNegative Net Change FULCNegative Net Change
biotechnology biotechs pharmaceuticals
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
by Kinjel Shah
FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.
REGNNegative Net Change SNYNegative Net Change JNJNegative Net Change NVONegative Net Change
pharmaceuticals
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
by Zacks Equity Research
AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.
ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change AURANegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
by Kinjel Shah
Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRPositive Net Change
pharmaceuticals
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
by Zacks Equity Research
Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
GSKPositive Net Change SMMTNegative Net Change IMVTNegative Net Change RLAYNegative Net Change TERNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
by Zacks Equity Research
NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
by Zacks Equity Research
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
JNJNegative Net Change LLYNegative Net Change ABBVPositive Net Change
biotechs immuno-therapy medical pharmaceuticals
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
by Ahan Chakraborty
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
NVSPositive Net Change RHHBYPositive Net Change PFENegative Net Change LLYNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals